Qirui Pharmaceutical’s Ganyining® Ademetionine Disulfonate for Injection Wins Bid in the 11th National Centralized Procurement Round

Recently, the 11th round of national centralized bulk procurement of drugs was officially opened for bidding in Shanghai, with Qirui Pharmaceutical’s Ganyining® Adenosine Methionine Disulfonate Successfully selected.

This centralized procurement initiative includes a total of 55 pharmaceutical products, covering commonly used medications in areas such as anti-infection, anti-allergy, anti-tumor, blood-glucose-lowering, blood-pressure-lowering, lipid-lowering, and anti-inflammatory analgesic therapies. A total of 46,000 medical institutions nationwide submitted quantity requests, and 794 products from 445 companies participated in the bidding. Ultimately, 453 products from 272 companies were shortlisted for selection, representing a company selection rate of 61% and a product selection rate of 57%. According to arrangements made by the National Healthcare Security Administration, it is expected that patients across the country will have access to this new batch of high-quality, cost-effective winning bids starting February 2026.

(Image source: Shanghai Sunshine Pharmaceutical Procurement Network)

Compared with previous rounds of national centralized procurement, the eleventh round has introduced optimizations in terms of eligibility requirements for participating companies, volume reporting, and procurement rules, fully adhering to the principle of “ensuring clinical stability and quality.” The company qualification review process now incorporates three-tiered quality thresholds, while a dual-track volume-reporting model—covering both generic names and specific brand names—is adopted. Priority is given to currently marketed products that enjoy clinical acceptance and consistent quality, which poses significant challenges for products newly launched in 2024.

According to data from the Shanghai Sunshine Pharmaceutical Procurement Network, a total of nine companies nationwide submitted bids for ademetionine injection, including the original research manufacturer and several well-known domestic pharmaceutical firms. Amid such intense competition among generic drug manufacturers, Qirui Pharmaceutical’s R&D–produced Ganyining® Ademetionine Disulfonate Injection has broken through the competitive barriers, successfully stood out from the crowd, secured a winning bid, and will be supplied to five provinces: Beijing, Liaoning, Jilin, Sichuan, and Qinghai.

Since the implementation of the national centralized drug procurement policy, Qirui Pharmaceutical has responded proactively and currently has three products selected for inclusion in the centralized procurement program. Going forward, Voriconazole Tablets Several products, including voriconazole for injection and tigecycline for injection, will further participate in the follow-up rounds of the national centralized procurement program.

Qirui Pharmaceutical has consistently upheld the mission of “providing high-quality, specialized products and services for human health.” Through technological innovation and lean manufacturing, the company strives to enhance product quality while reducing costs. This approach not only safeguards product quality and strengthens market competitiveness but also improves drug accessibility, alleviates the financial burden on patients, and ultimately benefits more patients across a broader range of disease areas.